Table 1.

The effect of Edaravone in patients with severe COVID-19 infection

	Control (n = 19)	Intervention (n = 19)	P value
Clinical parameters
Age (years)	59.35 ± 18.16	62.09 ± 9.55	0.65
Gender; men/women	9 (47.4%)/10 (52.6%)	9 (47.36%)/10 (52.63%)	0.749
Primary outcomes
Need for intubation	8 (42.1%)	2 (10.52%)	0.034
Intubation length (days)	28 (4–28)	3 (1–7)	0.047
ICU admission length (days)	10 (7–26)	11 (2–28)	0.917
Mortality	2 (10.5%)	3 (15.78%)	0.66

Quantitative variables were reported as mean ± SD or median (min–max) and qualitative variables were reported as number (percentage). Independent t-test or Mann–Whitney U test were utilized for data analysis and p value < 0.05 was considered significant